During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes ...

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its ...

Panelists discuss the INSEMA trial, comparing no axillary surgery versus axillary sentinel lymph node biopsy (SLNB) in patients with early invasive breast cancer, exploring the implications for ...

BCL-2 inhibitors, such as venetoclax (Venclexta) work by targeting the BCL-2 protein, which plays a key role in preventing ...

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the ...

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

Samer A. Al’Hadidi, MD, discusses social determinants and resources that can help patients receive chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.

Martin Dreyling, MD, discusses how the safety and efficacy results from the TRIANGLE study in mantle cell lymphoma differ from prior expectations.